Akebia Therapeutics to Report First Quarter Financial Results
Akebia Therapeutics (Nasdaq: AKBA) plans to release its first-quarter financial results for 2022 on May 9, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) plans to release its first-quarter financial results for 2022 on May 9, 2022, after market close. The company will hold a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Participants can join the call via phone or listen live on Akebia's website. A replay will be available shortly after the call concludes, lasting until May 15, 2022. Akebia focuses on developing therapeutics for individuals affected by kidney disease.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +3.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Akebia to Host Conference Call to Provide Business Update
CAMBRIDGE, Mass., May 2, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 following the close of financial markets.
Akebia will host a conference call Monday, May 9, 2022 at 4:30 p.m. ET to discuss its financial results and provide a general business update. To listen to the conference call on May 9th, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 1273066. The call will also be webcast LIVE and can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.
A replay of the conference call will be available two hours after the completion of the call through May 15, 2022. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 1273066. An online archive of the conference call can be accessed via the Investors section of Akebia's website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-first-quarter-financial-results-301536854.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.